Deals
Buyout Firm GTCR Is in Advanced Talks to Acquire German Drugmaker Stada
- Buyout firm in pole position after rival bidder CD&R drops out
- Deal agreement could be reached as soon as this month
This article is for subscribers only.
Buyout firm GTCR is in advanced talks on a potential acquisition of German generic drugmaker Stada Arzneimittel AG, people with knowledge of the matter said.
GTCR is seeking to hammer out terms of a deal after rival bidder Clayton Dubilier & Rice dropped out of the race, the people said, asking not to be identified because the information is private. It has been discussing a valuation of roughly €10 billion ($11 billion) for Stada, the people said.